Sarepta price target lowered to $184 from $215 at Oppenheimer
Oppenheimer analyst Andreas Argyrides lowered the firm’s price target on Sarepta (SRPT) to $184 from $215 and keeps an Outperform rating on the ...
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like ...
Sarepta Therapeutics (SRPT) Receives a Hold from Scotiabank
Scotiabank analyst Louise Chen maintained a Hold rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...
Clinical Trials Arena14h
Sarepta and Roche aim to resume paused Elevidys trials following patient death
Sarepta and Roche announced a 16-year-old US patient dosed with Elevidys died of acute liver failure in March 2025.
LPL Financial LLC Has $6.50 Million Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
LPL Financial LLC grew its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 12.4% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 53,438 shares ...